Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK - Wikidata - awgldk - TriplyDB

Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK

Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK

http://www.wikidata.org/entity/Q29615472

about

Molecular biology of lung cancer Crizotinib: A comprehensive review Clinical use of crizotinib for the treatment of non-small cell lung cancer The biology and treatment of EML4-ALK non-small cell lung cancer Crizotinib resistance: implications for therapeutic strategies Personalized Clinical Trials in Hepatocellular Carcinoma Based on Biomarker Selection Targeted therapies and immunotherapy in non-small-cell lung cancer Tackling ALK in non-small cell lung cancer: the role of novel inhibitors Tyrosine Kinase Receptor Landscape in Lung Cancer: Therapeutical Implications Overcoming resistance to first/second generation epidermal growth factor receptor tyrosine kinase inhibitors and ALK inhibitors in oncogene-addicted advanced non-small cell lung cancer Recent Advances in Targetable Therapeutics in Metastatic Non-Squamous NSCLC MicroRNA In Lung Cancer: Novel Biomarkers and Potential Tools for Treatment Molecular mechanisms that underpin EML4-ALK driven cancers and their response to targeted drugs ALK inhibitors in non-small cell lung cancer: the latest evidence and developments ALK and ROS1 as targeted therapy paradigms and clinical implications to overcome crizotinib resistance Personalized treatment options for ALK-positive metastatic non-small-cell lung cancer: potential role for Ceritinib The distinctive nature of adenocarcinoma of the lung Progress of EGFR-TKI and ALK/ROS1 inhibitors in advanced non-small cell lung cancer Patterns of Chromosomal Aberrations in Solid Tumors Differences in driver genes between smoking-related and non-smoking-related lung cancer in the Chinese population The Evolution of Therapies in Non-Small Cell Lung Cancer Treating patients with ALK-positive non-small cell lung cancer: latest evidence and management strategy Current and future molecular profiling of cancer by next-generation sequencing Targeted therapies for patients with advanced NSCLC harboring wild-type EGFR: what's new and what's enough Using large-scale genomics data to identify driver mutations in lung cancer: methods and challenges ALK-positive non-small cell lung cancer: mechanisms of resistance and emerging treatment options Predictive biomarkers in precision medicine and drug development against lung cancer Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Adult lung stem cells and their contribution to lung tumourigenesis Systemic and targeted therapies for early-stage lung cancer Non-coding RNAs in lung cancer Personalised cancer medicine Targeting EML4-ALK driven non-small cell lung cancer (NSCLC)Tumor heterogeneity and resistance to EGFR-targeted therapy in advanced nonsmall cell lung cancer: challenges and perspectives Review of the current targeted therapies for non-small-cell lung cancer Targeted therapies in development for non-small cell lung cancer Role of molecular studies in the diagnosis of lung adenocarcinoma Advances of molecular subtype and targeted therapy of lung cancer Molecular pathology of lung cancer: key to personalized medicine.Activity of IPI-504, a novel heat-shock protein 90 inhibitor, in patients with molecularly defined non-small-cell lung cancer.

P2860

Q24606677-A9A4A20E-FE94-401A-AEFF-89BBC81E7832 Q24624083-790636D6-22BF-409A-BE9C-A8113BD178A1 Q24630466-619AA9AA-D947-4B86-9A9D-74841705DB97 Q24632625-6B9D896C-29F8-48D6-8EC6-4B65E7636073 Q26738381-5C9898E9-B79C-456D-B5CC-225BE6FE13DB Q26738860-9427CD9E-EE58-435C-BA96-B3B2AB6C370A Q26738986-F359AD43-1857-4ED5-B27F-F944E62EA072 Q26740329-1FAE5230-66EE-46DC-AD6E-E18B983D7F3B Q26741318-0B0140CC-D7BB-44E1-B25C-55F25F2B2C74 Q26745427-9479F246-81E0-4B99-97D3-5BFBF40B0610 Q26747276-AFAFE35E-A440-4D36-9D46-4805F1699E4B Q26752548-8A46287C-4B28-476D-8697-7AB61FB938FA Q26769659-F44A69BA-A5FF-4D41-94FA-147600574D27 Q26769879-AA86A73C-FEFE-481C-B6E3-A291BA5855F0 Q26775347-AC369D11-D554-4B9B-815E-D64FFDEB2942 Q26775817-605AD250-66E8-4D72-A919-8F674178872E Q26781159-4AFDC6C5-F6C2-4F8C-AFA5-2BCBADDADC6B Q26784298-1ED30FBE-2F33-4382-AADD-BEB33B359A55 Q26786127-FDBB96F5-5DAA-42C3-8E89-8802E77CA84B Q26786594-12D105F7-66FD-476B-94C9-6BC64C799F74 Q26786932-9803A68A-9B28-446F-B47A-130B48FB3ACF Q26795555-069AB178-070E-4604-9A21-C111879A9DFB Q26796272-2B0AA8CB-CC0D-4CD0-BECB-57387BB5D660 Q26799467-C767E33B-9542-4444-A932-1A16720E57B6 Q26800833-FFD41969-200B-4962-A40A-991C9D741BC1 Q26820845-85EA4DFC-96AD-470D-BFA6-C787135B7792 Q26824536-3169D59F-C589-4B9D-8242-A108CAA39A19 Q26828860-7AD71B34-BA41-4599-A0A1-A3EC070DD234 Q26830034-DABF5369-8FE5-460A-A5FC-BAABF23F3FCB Q26865490-5A5A4DF7-5AA1-4557-897D-10DE6EABE7D6 Q26866521-F08A06B4-7685-418F-85DB-AE1C7BC9E695 Q26991908-18933CB5-DC9B-4D92-85EA-3C25A94FD0DB Q27002155-134E4846-BBA8-4D07-B4F2-3062D784A5C9 Q27014117-79A9C79B-227C-49A5-904F-01AAE3205DEC Q27015079-FFAE4A22-FE22-4FA4-8320-734587CEEAA5 Q27022852-FFA47064-871F-4650-B06E-25F693C86224 Q27023212-1F773FF9-BE5F-4A84-B22E-75B08BD8552D Q27030813-F73EBCA6-1C5F-4754-AF58-01C3A2BE2A47 Q27691299-DC3BD18E-21AC-467B-B4F6-7CE6DF42943E Q27851585-50A3012F-F666-4C52-86F3-A362DB096BBB

P2860

Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK

http://www.wikidata.org/entity/Q29615472

description

2009 nî lūn-bûn

@nan

2009 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Clinical features and outcome ...... ung cancer who harbor EML4-ALK

@ast

Clinical features and outcome ...... ung cancer who harbor EML4-ALK

@en

type

label

Clinical features and outcome ...... ung cancer who harbor EML4-ALK

@ast

Clinical features and outcome ...... ung cancer who harbor EML4-ALK

@en

prefLabel

Clinical features and outcome ...... ung cancer who harbor EML4-ALK

@ast

Clinical features and outcome ...... ung cancer who harbor EML4-ALK

@en

P1433

Q29615472-D267E40B-60B5-4EE3-9E36-9478921CF755

P1476

Q29615472-65E56341-D9F6-41BB-9C26-68FA4AC2CBB9

P2093

Q29615472-1173BBA2-E9E8-4DCC-A66A-750AD6EA62A8

Q29615472-1666FEFC-9A45-4A0F-A99A-56CCD01C3235

Q29615472-1F6C0DCC-C82D-410C-9376-48642AD1AF39

Q29615472-2C962D1E-8968-4F9D-98DD-F213BB389E19

Q29615472-2D12CA1E-329F-4BA9-95B0-B163FB93F9D5

Q29615472-5AE3C386-2874-45F8-AE28-69380998AE50

Q29615472-6810F8B9-976C-4F1B-9B48-206DC87DFD45

Q29615472-6F8B1C41-3C90-49FC-AEE6-AC18C36F9802

Q29615472-72D13D9B-9C7C-4832-BC9D-A3DB46AAA166

Q29615472-774A1B41-1A30-4635-999D-D1D39030C55E

P2860

Q29615472-1F542610-EF2F-4FF0-AB11-9ECEBF552E17

Q29615472-24EDB6A8-D3BE-4624-B78B-A309BE93B3DC

Q29615472-281A932D-7EEA-422F-8EF6-058B9A68E690

Q29615472-29984E8D-CCC0-4C70-9C33-737BAAB9D2EA

Q29615472-2A9EF4DB-BE22-4D5B-B9D9-DB6CE11682E9

Q29615472-2AD813E4-9333-4CE8-87B1-56C71D0C345B

Q29615472-4A531D09-D031-4125-B52F-39F57C2B4F59

Q29615472-50E8D956-618F-4B9B-A690-9F11443ECB79

Q29615472-5CA12ED0-30DD-4CE5-A172-A1174177D7AA

Q29615472-6DDD6DD0-B8A7-40AE-801F-FE466E5A26FA

P304

Q29615472-C5DF0AD6-BCA9-462B-B9B7-4F23230FB2D0

P31

Q29615472-703E0E04-CE1C-4150-B9BC-9EC54D7B6B82

P3181

Q29615472-229496AE-F430-43F1-A4EE-E36EAD664D01

P356

Q29615472-762C4BDD-A597-448A-854B-E54957A0FAD2

P407

Q29615472-17DCAE0E-352C-451A-A7C0-F027EAC6E852

P433

Q29615472-1DAE4B27-CF7D-4EF2-B38C-029F2A634BF2

P478

Q29615472-0983AD3A-594A-457F-BD93-37A6BC672589

P577

Q29615472-4C5C726D-9682-4483-AD7D-3FB4F3B197EB

P5875

Q29615472-3479F3A2-925F-45D2-A89C-6A1C2B430A3D

P698

Q29615472-38506E96-32D9-424D-B11B-860B4550EB3C

P932

Q29615472-F57CDDBD-2CDE-45F2-8AD8-1C6C9A334164

P3181

P356

JCO.2009.22.6993

P1433

Journal of Clinical Oncology

P1476

Clinical features and outcome ...... ung cancer who harbor EML4-ALK

@en

P2093

Admane S

http://www.w3.org/2001/XMLSchema#string

Chirieac LR

http://www.w3.org/2001/XMLSchema#string

Costa DB

http://www.w3.org/2001/XMLSchema#string

Digumarthy SR

http://www.w3.org/2001/XMLSchema#string

Heist RS

http://www.w3.org/2001/XMLSchema#string

Iafrate AJ

http://www.w3.org/2001/XMLSchema#string

Kobayashi S

http://www.w3.org/2001/XMLSchema#string

Kwak EL

http://www.w3.org/2001/XMLSchema#string

Lynch TJ

http://www.w3.org/2001/XMLSchema#string

Mark EJ

http://www.w3.org/2001/XMLSchema#string

P2860

KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib

Global and regional estimates of cancer mortality and incidence by site: II. Results for the global burden of disease 2000

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.

Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer.

Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma.

Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors.

EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer.

Multiplex reverse transcription-PCR screening for EML4-ALK fusion transcripts.

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

P304

4247-53

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

559972

http://www.w3.org/2001/XMLSchema#string

P356

10.1200/JCO.2009.22.6993

http://www.w3.org/2001/XMLSchema#string

P407

P433

26

http://www.w3.org/2001/XMLSchema#string

P478

27

http://www.w3.org/2001/XMLSchema#string

P577

2009-09-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

26729110

http://www.w3.org/2001/XMLSchema#string

P698

19667264

http://www.w3.org/2001/XMLSchema#string

P932

2744268

http://www.w3.org/2001/XMLSchema#string